| Autor: |
D J, Lewis, J E, Eiden, C, Goilav, A G, Langenberg, F, Suggett, G E, Griffin |
| Rok vydání: |
2004 |
| Předmět: |
|
| Zdroj: |
Communicable disease and public health. 6(4) |
| ISSN: |
1462-1843 |
| Popis: |
The ability of three doses of a novel MF59-adjuvanted hepatitis B virus (HBV) vaccine containing surface and pre-S2 antigens given at 0, 1, and 6 months to induce levels of HBV surface antibody (sAb)or = 100 mIU/ml was compared with a UK licensed alum-adjuvanted yeast-derived HBV vaccine in HBV-naive healthcare workers (HCWs). One month after second immunization with HBV/MF59, 100% of HCWs had sAbor = 100 mIU/mL, compared with only 11% and 85% after two or three immunisations with Engerix-B. The sAb GMT of the Engerix B immunised group remained below 100 mIU/mL until month seven, (compared with month one for HBV/MF59), and was 123-fold lower at this time (208,561 vs. 1,686 mIU/mL). In our subjects HBV/MF59 vaccine rapidly induced sAb to levels far in excess of those recommended by the Department of Health for high-risk situations (e.g. HCWs and patients on dialysis). It has the potential for shorter schedules and reduced need for serology and boosters. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
